Intranasal administration avoids first-pass metabolism and is popular in research settings, but the delivered fraction is small and highly formulation-dependent.
Key Takeaways
- The nasal mucosa is vascular and accessible, and it bypasses hepatic first-pass metabolism.
- Permeation enhancers, mucoadhesive polymers, and cyclodextrins are the main tools.
- Published nasal bioavailability values vary widely because of differences in device, formulation, and study design.
Why the route is attractive
The nasal mucosa is vascular and accessible, and it bypasses hepatic first-pass metabolism. For peptides that would otherwise require injection, the route offers a non-invasive alternative with rapid onset, which explains its popularity in both research and development.
What limits absorption
The nasal cavity clears formulations by mucociliary action within a short window, and the epithelial barrier excludes hydrophilic molecules. Enzymatic degradation in the mucosa further reduces the fraction reaching systemic circulation.
For related mechanism work, see peptide PEGylation.
Absorption-enhancing approaches
Permeation enhancers, mucoadhesive polymers, and cyclodextrins are the main tools. Each extends residence time or transiently modifies the epithelium, and each brings its own tolerability question that must be assessed rather than assumed.
Device and plume geometry matter
Where the dose deposits determines how much is absorbed. Droplet size, spray angle, and plume geometry are as influential as the formulation itself, which is why device selection belongs in early development rather than at the end.
Interpreting reported bioavailability
Published nasal bioavailability values vary widely because of differences in device, formulation, and study design. Compare only studies using comparable delivery systems, and be sceptical of figures quoted without the device described.
Experimental Conditions and Practical Setup
Absorption is assessed in an appropriate animal model with the formulation administered by a defined device, and plasma sampled at short intervals because onset is rapid and clearance is fast. The peptide is quantified by LC-MS, and any study reporting bioavailability is checked for a device description before its values are compared with another.
Variables that dominate nasal absorption
| Variable | Effect | Design response |
|---|---|---|
| Droplet size | Determines deposition region | Fix and report the device |
| Mucociliary clearance | Limits residence time | Add mucoadhesive polymer |
| Enzymatic degradation | Reduces intact fraction | Consider inhibitor or carrier |
| Formulation pH | Affects both stability and tolerance | Set within a tolerable window |
Practical Notes for the Bench
- Select the delivery device early, since plume geometry drives deposition.
- Account for mucociliary clearance when interpreting absorption data.
- Compare bioavailability only across studies using comparable devices.
Frequently Asked Questions
How much of a nasal dose is typically absorbed?
Usually a small fraction, and the value depends so heavily on formulation and device that cross-study comparison is unreliable without detail.
What limits nasal absorption most?
Rapid mucociliary clearance combined with poor epithelial permeability for hydrophilic molecules.
Do cyclodextrins help?
They can improve solubility and permeation, but the effect is peptide-specific and needs demonstrating for each case.
Why do published nasal bioavailability values disagree so widely?
Because device geometry, formulation, and sampling schedule all differ between studies. Values are only comparable when the delivery system is described in detail.
Related Reading
- peptide PEGylation
- peptide excipient compatibility
- transdermal peptide delivery
- peptide aggregation detection
- exorphin opioid peptides
References & Further Reading
- Majie A et al. Advanced intranasal peptide delivery systems for improved management of Alzheimer’s disease. Biomater Adv. 2026. PubMed 40885031
- Feng Q et al. Intranasal Delivery of Pure Nanodrug Loaded Liposomes for Alzheimer’s Disease Treatment by Efficiently Regulating Microglial Polarization. Small. 2024. PubMed 39370581
- Yin C et al. Intranasal delivery of peptide-modified quercetin liposomes suppresses neuroinflammation. J Control Release. 2026. PubMed 41621759
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- USP general chapters on pharmaceutical analysis
All material on this page is intended for laboratory research and educational reference only. It is not medical advice, and it does not describe any approved diagnostic or therapeutic use.
Reviewed by Dr. Aiko Tanaka, Bioactive Peptides & Dermatological Research.